Sonoma Pharmaceuticals annual gross margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Sonoma Pharmaceuticals Gross Margin Growth & History (SNOA)
Sonoma Pharmaceuticals's gross margin was 37.97% for fiscal 2026.
View full Sonoma Pharmaceuticals company overviewSonoma Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | 37.97% | −0.28 pp |
| 2025 | 2025-03-31 | 38.25% | +0.99 pp |
| 2024 | 2024-03-31 | 37.26% | +3.53 pp |
| 2023 | 2023-03-31 | 33.73% | +2.11 pp |
| 2022 | 2022-03-31 | 31.62% | −3.59 pp |
| 2021 | 2021-03-31 | 35.21% | −10.09 pp |
| 2020 | 2020-03-31 | 45.30% | −1.51 pp |
| 2019 | 2019-03-31 | 46.81% | +2.93 pp |
| 2018 | 2018-03-31 | 43.88% | −0.31 pp |
| 2017 | 2017-03-31 | 44.19% | +15.93 pp |
| 2016 | 2016-03-31 | 28.26% | −24.34 pp |
| 2015 | 2015-03-31 | 52.61% | −8.83 pp |
| 2014 | 2014-03-31 | 61.44% | −8.09 pp |
| 2013 | 2013-03-31 | 69.52% | +1.15 pp |
| 2012 | 2012-03-31 | 68.38% | +5.42 pp |
| 2011 | 2011-03-31 | 62.96% | — |
Sonoma Pharmaceuticals quarterly gross margin
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-30 | 40.23% | +3.76 pp |
| Q4 2026 | 2026-03-31 | 39.22% | −1.48 pp |
| Q3 2026 | 2025-12-31 | 37.94% | +2.31 pp |
| Q2 2026 | 2025-09-30 | 37.83% | −0.20 pp |
| Q1 2026 | 2025-06-30 | 36.46% | −2.05 pp |
| Q4 2025 | 2025-03-31 | 40.70% | +8.98 pp |
| Q3 2025 | 2024-12-31 | 35.63% | −10.89 pp |
| Q2 2025 | 2024-09-30 | 38.03% | +1.78 pp |
| Q1 2025 | 2024-06-30 | 38.51% | +3.38 pp |
| Q4 2024 | 2024-03-31 | 31.72% | +16.33 pp |
| Q3 2024 | 2023-12-31 | 46.53% | +18.30 pp |
| Q2 2024 | 2023-09-30 | 36.25% | −9.86 pp |
| Q1 2024 | 2023-06-30 | 35.13% | −6.19 pp |
| Q4 2023 | 2023-03-31 | 15.39% | +11.22 pp |
| Q3 2023 | 2022-12-31 | 28.23% | −13.23 pp |
| Q2 2023 | 2022-09-30 | 46.11% | +12.97 pp |
| Q1 2023 | 2022-06-30 | 41.33% | +1.88 pp |
| Q4 2022 | 2022-03-31 | 4.18% | +13.13 pp |
| Q3 2022 | 2021-12-31 | 41.45% | +1.04 pp |
| Q2 2022 | 2021-09-30 | 33.15% | −10.22 pp |
| Q1 2022 | 2021-06-30 | 39.44% | +0.34 pp |
| Q4 2021 | 2021-03-31 | −8.95% | −47.29 pp |
| Q3 2021 | 2020-12-31 | 40.42% | −5.11 pp |
| Q2 2021 | 2020-09-30 | 43.37% | −2.64 pp |
| Q1 2021 | 2020-06-30 | 39.10% | −11.91 pp |
| Q4 2020 | 2020-03-31 | 38.34% | −4.44 pp |
| Q3 2020 | 2019-12-31 | 45.53% | −8.39 pp |
| Q2 2020 | 2019-09-30 | 46.01% | −3.13 pp |
| Q1 2020 | 2019-06-30 | 51.01% | +11.39 pp |
| Q4 2019 | 2019-03-31 | 42.79% | +6.35 pp |
| Q3 2019 | 2018-12-31 | 53.92% | +5.03 pp |
| Q2 2019 | 2018-09-30 | 49.14% | +6.41 pp |
| Q1 2019 | 2018-06-30 | 39.62% | −6.33 pp |
| Q4 2018 | 2018-03-31 | 36.44% | −11.84 pp |
| Q3 2018 | 2017-12-31 | 48.90% | −1.86 pp |
| Q2 2018 | 2017-09-30 | 42.73% | +5.70 pp |
| Q1 2018 | 2017-06-30 | 45.95% | +8.76 pp |
| Q4 2017 | 2017-03-31 | 48.29% | +29.96 pp |
| Q3 2017 | 2016-12-31 | 50.76% | −0.80 pp |
| Q2 2017 | 2016-09-30 | 37.03% | −13.87 pp |
| Q1 2017 | 2016-06-30 | 37.19% | −12.91 pp |
| Q3 2016 | 2015-12-31 | 18.32% | −33.14 pp |
| Q2 2016 | 2015-09-30 | 51.55% | −1.51 pp |
| Q1 2016 | 2015-06-30 | 50.90% | −5.29 pp |
| Q4 2015 | 2015-03-31 | 50.10% | +2.64 pp |
| Q3 2015 | 2014-12-31 | 51.46% | −12.58 pp |
| Q2 2015 | 2014-09-30 | 53.06% | −13.09 pp |
| Q1 2015 | 2014-06-30 | 56.19% | −9.05 pp |
| Q4 2014 | 2014-03-31 | 47.46% | −18.15 pp |
| Q3 2014 | 2013-12-31 | 64.04% | −5.76 pp |
| Q2 2014 | 2013-09-30 | 66.15% | −4.55 pp |
| Q1 2014 | 2013-06-30 | 65.24% | −5.95 pp |
| Q4 2013 | 2013-03-31 | 65.61% | +1.89 pp |
| Q3 2013 | 2012-12-31 | 69.80% | +3.42 pp |
| Q2 2013 | 2012-09-30 | 70.70% | −5.14 pp |
| Q1 2013 | 2012-06-30 | 71.19% | +4.90 pp |
| Q4 2012 | 2012-03-31 | 63.71% | −7.48 pp |
| Q3 2012 | 2011-12-31 | 66.38% | +16.70 pp |
| Q2 2012 | 2011-09-30 | 75.84% | +8.00 pp |
| Q1 2012 | 2011-06-30 | 66.29% | +4.94 pp |
| Q4 2011 | 2011-03-31 | 71.19% | — |
| Q3 2011 | 2010-12-31 | 49.68% | — |
| Q2 2011 | 2010-09-30 | 67.84% | — |
| Q1 2011 | 2010-06-30 | 61.35% | — |
Sonoma Pharmaceuticals gross margin trends
Over the last five reported fiscal years, Sonoma Pharmaceuticals's gross margin increased from 35.21% to 37.97%, a change of +2.76 percentage points. The latest reported quarter, Q1 2027, shows 40.23%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sonoma Pharmaceuticals filings at SEC.gov ↗